Human Capital Pulse: Life Sciences | March 2026: The job-switch premium, bigger bonuses and Takeda's ¥200bn reset
March 2026 for Life Sciences HR: the job-switch pay premium, bonuses up 24%, Takeda's restructuring and Pay & Rewards benchmarks across ten sector peers.
HUMAN CAPITAL PULSE: LIFE SCIENCES · ISSUE 3 · MARCH 2026
A monthly Human Capital benchmark for HR and People leaders in Life Sciences: the sector's talking points and how culture, workforce and talent compare across your peers, built on Deltabase data covering 5,500+ companies and 11M employee reviews.
Editor's note
March put reward in the spotlight. BioSpace's annual salary survey found that changing employer pays far better than staying, and that bonuses rose even as average base pay fell. Takeda, meanwhile, launched a multiyear transformation to fund its launches. Reward is one of the sector's strongest culture topics, which makes it worth protecting when budgets tighten. This month we compare Pay & Rewards sentiment with the reward expertise peers hold in-house.
Leroy Hall, Deltabase
The month in three
1. Moving employer pays more than staying
What happened: BioSpace's 2026 US Life Sciences Salary Report found that 75.1% of job changers received a rise of at least 6%, against 22.6% of those given performance-based rises. The most common merit rise was 3%, and 68% of respondents believe they would need to change employer to get a rise they would be satisfied with.
The Deltabase lens: Culture: Pay & Rewards is a sector strength. Median Pay & Rewards NSS across ten Life Sciences Top 100 companies rose from +47.5% to +49.5% in 2025, with eight of the ten improving. Workforce: People are moving less: average monthly turnover at Novartis fell from 0.8% in January–February 2025 to 0.6% in January–February 2026.
So what: Positive reward sentiment can mask a retention gap; test whether your merit budget competes with the job-switch premium for critical roles.
2. Bonuses rise as base pay falls
What happened: The same survey found the average full-time salary fell 6% to $149,945 in 2025, while the average bonus rose 24% to $37,113, the highest in the five years reported. 61% of respondents received a rise, most often merit-based.
The Deltabase lens: Talent: Reward expertise is thin everywhere: benefits management skills are listed by 1.3% of AbbVie's people, 1.0% at Bristol Myers Squibb and 0.5% at Pfizer. Workforce: HR teams are also lean, at 1.9% of the workforce at AstraZeneca and GSK, against 3.5% at AbbVie and 3.2% at Eli Lilly.
So what: When more of the package sits in variable pay, people need to understand it; invest in reward communication, not just the numbers.
3. Takeda launches a ¥200bn transformation
What happened: On 25 March Takeda outlined a multiyear restructuring aimed at more than ¥200bn (about $1.26bn) in annual savings, to fund launches and R&D. A Massachusetts WARN notice covers about 634 US roles, a total Takeda says may change as employees accept redeployment; most changes take effect from July 2026.
The Deltabase lens: Culture: Restructures collide with the sector's weakest topic. Agility & Bureaucracy had a median NSS of −65.7% in 2025, the most negative of the 12 topics, and only three of ten peers improved.
So what: Savings programmes that add process will be read as bureaucracy; show employees what gets simpler.
Stat of the month
+49.5%: median Pay & Rewards NSS across ten Life Sciences Top 100 companies in 2025, up from +47.5%, with eight of the ten improving.
| Company | Culture: Pay & Rewards NSS 2025 | Culture: change vs 2024 | Talent: % with benefits management skills |
|---|---|---|---|
| Bristol Myers Squibb | +58.3% | +2.2 pts | 1.0% |
| AbbVie | +56.5% | +5.9 pts | 1.3% |
| AstraZeneca | +49.7% | +6.8 pts | 0.8% |
| GSK | +49.0% | −2.3 pts | 0.7% |
| Pfizer | +46.6% | +10.4 pts | 0.5% |
| Eli Lilly | +43.6% | +10.6 pts | 0.9% |
Source: Deltabase Culture data, Employee Net Sentiment Score (−100% to +100%), 2024–2025; sector median of AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, Johnson & Johnson, Novartis, Pfizer and Sanofi. Deltabase Talent data, share of workforce listing benefits management skills.
Spotlight: Novartis vs Sanofi
Europe's two culture leaders in the peer set. On Culture, Sanofi had the highest overall NSS among the ten peers in 2025, up from +17.2% to +21.4% (1,191 reviews), and the highest Pay & Rewards score at +63.2%. Novartis was second at +14.9% (899 reviews), with Pay & Rewards up 11.7 pts to +54.9%, the largest gain in the peer set, and a much stronger Work-Life Balance score (+23.5% against +6.0%). On Workforce, both are growing and holding on to people: headcount rose +7.7% at Novartis and +8.2% at Sanofi between December 2024 and February 2026, and average monthly turnover in January–February fell to 0.6% at both, from 0.8% and 0.9%. On Talent, 1.0% of Novartis's people list benefits management skills, against 0.7% at Sanofi.
For your People team
- Price the job-switch premium into retention offers for scarce roles; a 3% merit round will not hold them.
- Explain variable pay clearly: show people how bonuses are earned and what they were worth last year.
- Pair any savings programme with a visible list of processes being removed.
See how your Human Capital compares with your Life Sciences peers. Book a 30-minute benchmark walkthrough across culture, workforce and talent. Book a walkthrough →
Sources: BioSpace (19 March 2026); Fierce Pharma (March 2026); Deltabase Culture data; Deltabase Workforce data; Deltabase Talent data; Deltabase Employee Turnover data.